Clinical Trial Update: DEFLECT II: A Study to Evaluate the Safety and Performance of the TriGuard™HDH in Patients Undergoing TAVR [NA]

View source ↗

Summary

DEFLECT II studied the safety and performance of the TriGuard HDH device during transcatheter aortic valve replacement; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aortic Valve Stenosis

Drugs mentioned

• TriGuard HDH

Snippet

Sponsor: Keystone Heart | Conditions: Aortic Valve Stenosis | NA | Status: COMPLETED